NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT02633800 2019-01-07Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )Daiichi SankyoPhase 2 Terminated87 enrolled 13 charts